Ciraparantag TFA  (Synonyms: PER977 TFA)

Ciraparantag TFA is a thrombin and factor Xa inhibitor. Ciraparantag TFA is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban^[1][2][3][4].

thrombin, factor Xa^[1]

Ciraparantag TFA is a small-molecule antidote for unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), and certain direct oral anticoagulants (DOACs)^[2].
Ciraparantag TFA is a small synthetic and cationic molecule that binds direct Xa inhibitors, direct thrombin inhibitors, and unfractionated and low molecular weight heparin (LMWH) through non-covalent hydrogen bonds and charge–charge interactions^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

740.74

C₂₆H₅₀F₆N₁₂O₆

1438492-27-3

O=C(NCCCN1CCN(CCCNC([C@@H](N)CCCNC(N)=N)=O)CC1)[C@@H](N)CCCNC(N)=N.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Das A, et al. Novel antidotes for target specific oral anticoagulants. Exp Hematol Oncol. 2015 Sep 15;4:25.  [Content Brief]

  [2]. Gomez-Outes A, et al. Specific antidotes in development for reversal of novel anticoagulants: a review. Recent Pat Cardiovasc Drug Discov. 2014;9(1):2-10.  [Content Brief]

  [3]. Hu TY, et al. Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. Vasc Health Risk Manag. 2016 Feb 17;12:35-44.  [Content Brief]

  [4]. Honickel M, et al. The Reversal of Direct Oral Anticoagulants in Animal Models. Shock. 2017 Aug;48(2):144-158.  [Content Brief]